Lymphocyte profiles after a first demyelinating event suggestive of multiple sclerosis reveal early monocyte and B cell alterations

*‡*Cesar Alvarez-Gonzalez[1,2], *Annika Wiedemann[3,4], *Maria Schroeder-Castagno[2,5,6], Steven Schepanski[9], Susanna Asseyer[1,5,6], Claudia Chien[1,5,6,8], Joseph Kuchling[1,5,7], Judith Bellmann-Strobl[1,5,6], Klemens Ruprecht[7], Carmen Infante-Duarte[2,5,6], **Thomas Dörner[3,4], **‡Friedemann Paul[1,5,6,7]

*First joint authors
** Joint senior authors
‡ Joint Correspondent Authors

1. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Neuroscience Clinical Research Center, 10117 Berlin, Germany

2. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute for Medical Immunology, 13353 Berlin, Germany

3. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Medicine/Rheumatology and Clinical Immunology, Berlin, Germany

4. German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany

5. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, ECRC Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Lindenberger Weg 80, 13125 Berlin, Germany

6. Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

7. Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Neurology, 10117 Berlin, Germany

8. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Psychiatry and Neurosciences, 10117 Berlin, Germany

9. Department of Pediatrics, Division of Oncology and Hematology, Charité Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany

Abstract

Introduction. Often, an isolated clinical event suggestive of CNS demyelination confers a risk of conversion to multiple sclerosis. In this study, we investigate lymphocyte profiles after a first clinical event suggestive of multiple sclerosis (MS), which could contribute to the current understanding of early inflammatory responses in this demyelinating disease.

Methods. Twenty treatment-naïve clinically isolated syndrome (CIS) patients and fifteen healthy participants were included in our assessment of lymphocyte profiles and B cell subsets using multicolour flow cytometry. Analysis was made at 3-6 months (Baseline), 12, and 24 months after a first clinical event. We also performed a sub-analysis of patients that received glatiramer acetate (GLAT) after their baseline visit up to 24 months after the first clinical event.

Results. Our analysis revealed monocyte and B cell differences between groups. Percentages of $CD19^+CD20^+$ B cells were lower in CIS patients compared to healthy individuals at baseline. Additionally, monocyte distribution among groups was different. A subgroup analysis of patients treated with GLAT (n= 10) showed an increased percentage of naïve (p<0.05) and memory pre-switched (p<0.01) B cells up to 24 months after their baseline visit compared to the untreated group (n= 10).

Conclusion. Our results showed early monocyte and B cell subsets alterations in pwCIS. Moreover, GLAT-treated patients showed an increased percentage of naïve and memory pre-switched B cells after 24 months of treatment. Further research is needed to elucidate the role of B cells and monocyte disturbances during inflammatory processes after a first clinically-MS suggestive event.

1. Introduction

Around 85% of patients with an acute neurological isolated clinical event (patients with clinically isolated syndrome or pwCIS) progress to multiple sclerosis (MS) (Lin et al., 2021; Pitt et al., 2022). Thus, the characterisation of lymphocyte subpopulations in the early stages of MS could – in conjunction with clinical and paraclinical data – contribute to our understanding of disease pathomechanisms and help develop biomarkers for treatment response and prognostication (Baker, Herrod, Alvarez-Gonzalez, Giovannoni, et al., 2017; Jager et al., 2008) .

Evidence from animal models of MS have long suggested that MS is a CD4 Th1/Th17 - cell-mediated disease. Nonetheless, current evidence indicates that B cells, other lymphocytes subpopulations, and monocytes contribute likewise significantly to the pathogenesis of MS (Baker et al., 2019; Bittner et al., 2017; Gelfand et al., 2017; Lassmann, 2019; Roodselaar et al., 2021). For instance, lymphocytic investigation from anti-CD20 therapies and oral cladribine (CLAD) studies showed that the decrease in disease activity could be attributed to the depletion of B cells and that the effect on T cells might not be as relevant as previously claimed (Baker, Herrod, Alvarez-Gonzalez, Zalewski, et al., 2017; Cellerino et al., 2020; Sèze et al., 2023; Staun-Ram et al., 2018).

Here, we aim to investigate phenotypic patterns of lymphocyte subsets after a first clinical event suggestive of MS. We hypothesised that analysis of lymphocyte profiles in treatment-naïve pwCIS may contribute to the development of clinically applicable biomarkers for treatment response and disease course prognostication. In addition, in a small explorative sub-analysis in pwCIS, we compared lymphocyte subpopulations between two groups: pwCIS receiving glatiramer acetate (GLAT) and pwCIS who remained untreated.

2. Patients & Methods

2.1 Patients

Twenty treatment-naïve pwCIS (without MS disease-modifying treatment) from the Berlin CIS cohort (NCT01371071), an ongoing prospective observational study initiated at Charité – Universitätsmedizin Berlin in 2011, were selected to assess lymphocyte profiles and B cell subsets by using multicolour flow cytometry. The inclusion criteria, as described previously (Gieß et al., 2017), were: >18 years of age and a first clinical event suggestive of demyelination of the CNS, according to the McDonald 2010 criteria (Polman et al., 2011), within the 6 first months before cohort enrolment. Exclusion criteria were inability or unwillingness to provide informed consent, incomplete collection of blood samples for follow-up, and a history of any health condition or devices impeding immunological, clinical, and radiological examination. Moreover, sample selection was also limited to those individuals with sufficient availability of frozen peripheral blood mononuclear cells (PBMCs). All participants provided written informed consent and ethics approval for this study was given by the institutional review board of Charité – Universitätsmedizin Berlin (EA1/180/10).

During the visits, all patients underwent clinical and magnetic resonance imaging (MRI) assessments and blood extraction for PBMCs isolation. The first visit (baseline visit) was scheduled between 3-6 months after a first clinical event suggestive of demyelination of the CNS according to the McDonald 2010 criteria, and before administration of GLAT. The second visit was performed at around 12 months after the first clinical event, and the third visit at around 24 months after the first clinical event. Out of twenty pwCIS, ten received GLAT after baseline visit (due to signs of disease activity), whilst the other half remained untreated. PBMCs were isolated using Biocoll separating solution and stored in liquid nitrogen according to standard operating procedures (SOP) at NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin. Frozen PBMCs from fifteen unmatched healthy donors (HDs) were used as controls. Disease activity was defined as the presence of new

lesions in T2-weighted and/or contrast-enhancing MRI, and/or new clinical events suggestive of demyelination of the CNS, and/or confirmed deterioration on EDSS at 12 and/or 24 months of follow-up.

2.2 Immunophenotyping

Frozen PBMCs samples were thawed and subsequently stained and analysed by flow cytometry. Briefly, a set of markers to discriminate between lymphocytic profiles and B cell subsets was established: CD3, CD4, CD14, CD19, CD20, CD25, CD27, CD38, CD127, CD138, IgD, and HLA-DR. A live/dead fixable blue dead cell stain kit (Invitrogen) was used per the manufacturer's instructions to identify dead cells. Cells were stained for 15 min at 4°C, washed and filtered before acquisition.

Stained samples were analysed on LSR Fortessa X-20 (LSRFortessa; BD Biosciences, USA). To ensure stable analysing conditions, flow cytometer setup and tracking beads from BD were used daily. Diva and FlowJo software (v10.4; BD, USA) were used to determine different subpopulations. Results are expressed as percentages. For details on antibodies and gating strategy (see **Supplementary Figure 1)**.

2.3 MRI acquisition and post-processing

All study subjects were scanned using 3 Tesla (Tim Trio; Siemens, Erlangen, Germany) MRI scanners at the Berlin Center for Advanced Neuroimaging. Pre- and post-contrast 3D T1-weighted magnetisation prepared rapid gradient-echo (MPRAGE) images (resolution $1 \times 1 \times 1$ mm^3; TR = 1,900 ms, TE = 3.03 ms, TI = 900 ms, flip angle 9°) and a 3D T2-weighted fluid -attenuated inversion recovery (FLAIR) images (resolution $1 \times 1 \times 1$ mm^3; TR = 6,000 ms, TE = 388 ms, TI = 2,100 ms, flip angle 120°) were acquired for each patient. MPRAGE and FLAIR were cropped, co-registered to MNI-152 space (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Fslutils#Tools), N4-bias corrected (http://stnava.github.io/ANTs/) and linearly co-registered with each other using FSL FLIRT (Greve & Fischl, 2009). Longitudinal co-registration was performed by using the same FSL

tools and each MPRAGE and FLAIR from follow-up scans per patient were co-registered to their baseline scan. T2-hyperintense and gadolinium contrast-enhancing lesions were segmented from FLAIR and post-contrast MPRAGE images manually using ITK-SNAP (Rasche et al., 2018) by 2 expert MRI technicians with more than 10 years of experience with multiple sclerosis lesion identification. Whole brain T2-hyperintense lesion count was extracted using FSL cluster.

2.4 Statistics

Statistical analysis was performed using JAMOVI for macOS (The jamovi project (2020). jamovi (v.2.5.1.0) [Computer Software]. Retrieved from https://www.jamovi.org) and Prism 8.4.2 (GraphPad, La Jolla, USA), and R version 4.3.2 (2023-10-31) Platform: aarch64-apple-darwin20 (64-bit) Running under: macOS Sonoma 14.4. Independent t-test and Mann-Whitney were used to compare percentages between two unpaired groups. A Shapiro-Wilk normality test was performed. A Fisher's exact test was used to analyse any difference between categorical variables. Unless stated otherwise, data shows mean percentage and standard deviation (SD).

Furthermore, a sub-analysis of lymphocytes in GLAT-treated and untreated pwCIS was performed using Analysis of Covariance (ANCOVA). The ANCOVA model was applied to evaluate the difference in quantified cell populations between GLAT-treated and untreated pwCIS groups at 24 months post-baseline. To control for potential confounding effects from earlier time points, the model included both baseline and 12-month quantifications as covariates. This approach allowed us to isolate the treatment effect at 24 months while accounting for variations at baseline and changes over the first 12 months.

The model was specified as follows: `outcome_24m ~ baseline + outcome_12m + treatment`, where `outcome_24m` represents the outcome measure at 24 months after baseline, `baseline` refers to the baseline measurement, `outcome_12m` is the 12 months measurement, and `treatment` indicates whether the participant received GLAT or not.

Prior to interpreting statistical differences between groups, the assumptions of ANCOVA, including normality of residuals using Shapiro-Wilk tests and homoscedasticity using Breusch-Pagan tests were formally tested. Data were defined as statistically significant when at least $p < 0.05$. Given small sample sizes, outlier detection was not performed, and thus not excluded from analysis.

3. Results

3.1 Demographics

Twenty pwCIS (male-to-female ratio 9:11) and fifteen HDs (male-to-female ratio 7:8) were included in this study (**Table 1**). No relevant difference between the two groups in sex (p=0.909) and age (p=0.548), was found. The baseline median EDSS for pwCIS was 2.00 (1.00 – 4.00) and 1.00 (0.00 – 2.50) for males and females, respectively. PBMCs from one CIS individual on baseline were not viable for flow cytometry analysis due to poor viability after thawing. Whilst in the GLAT group, disease activity was high at the baseline, no major differences in disease activity were found between groups at any time point afterwards (see Table 1 and **Supplementary Figure 2**).

3.2 Differences between treatment-naïve pwCIS and HDs at baseline

First, we analysed the difference between lymphocytes and monocytes in pwCIS and HDs at baseline. Results are shown in **Figure 1** and **Table 2 (descriptive results in supplement table 2)**. We found notable differences that showed lower percentages of lymphocytes in pwCIS compared to HDs **(Figure 1A;** 84.0 vs 91.7; [**% mean** $p\,\square$ 0.001]). In contrast, the frequency of monocytes was higher among pwCIS than HDs (**Figure 1A**; 16.0 vs 8.2, ; [**% mean** $p < 0.001$]).

Lymphocyte subsets were categorised as shown in **Figure 1**. Briefly, T cells were defined by the expression of CD3, monocytes by the expression of CD14 and B cells characterised by the absence of CD3 and CD14 with the expression of CD19 and CD20. Afterwards, a set of markers to discriminate between specific T and B cell subsets was established (see gating strategy in **Supplement Figure 1**). Our results did not show any difference in the mean percentage of $CD3^+$ (**Figure 1A**) or $CD3^+CD4^+$ T cells among groups (**Figure 1B**). However, the fraction of $CD4^+CD38^+HLADR^+$ within the T cell population was slightly higher in pwCIS (**Figure 1C**; 0.36 vs 0.23; [**% mean** $p=0.015$]). Moreover, the percentage of

CD4$^+$CD25^{high}/CD127^{low} cells (defining Tregs) in pwCIS was somewhat higher than in HDs (**Figure 1B**; 3.9 vs 2.6; [**% mean** p◻ 0.001]).

Interestingly, the percentage of CD19$^+$CD20$^+$ B cells among lymphocytes was notably lower in pwCIS compared to HDs (**Figure 1A**; 5.7 vs 9.3; [**% mean** p◻ 0.001]). Percentages of both, CD20$^+$CD27$^-$ naïve and CD20$^+$CD27$^+$ memory B cells, were higher in HDs (naïve= 4.0 and memory= 2.5; [**% mean**]) than in pwCIS (naïve= 6.6 and memory= 1.5; [**% mean**]) (**Figure 1D**; p◻ 0.001 and p◻ 0.01, respectively); however, there was no substantial difference between the percentages of CD19$^+$CD20$^-$CD27^{high} cells (Plasmablasts; **Figure 1D**).

When we compared the proportions of B cell subsets defined by CD27 and IgD markers (CD27$^-$IgD$^+$ naïve, CD27$^+$IgD$^+$ pre-switched memory, CD27$^+$IgD$^-$ switched memory, and CD27$^-$IgD$^-$ double negative) between pwCIS and HDs, we did not find any substantial difference among these cohorts (**Figure 1E**).

3.3 Sub-analysis of lymphocytes in treated-GLAT and untreated pwCIS

Using ANCOVA analyses, we compared lymphocyte subsets and monocytes in two subgroups of patients: those who were untreated (n=10) and those who received glatiramer acetate (GLAT; n=10). While controlling for baseline (3-6 months) and 12-month quantifications as covariates, the outcomes analysed for the two subgroups of patients were at 24 months after the first clinical event suggestive of demyelination of CNS. Results from ANCOVA analyses are depicted in **Table 3 (descriptive results in Supplement Table 3 and Supplement Figures 4 and 5)**.

First, we analysed the difference between lymphocytes and monocytes in pwCIS at 24 months. We, nonetheless, did not find any important changes among groups.

We categorised lymphocyte subsets as shown in **Table 3** (see also gating strategy in **Supplement Figure 1**). Our analysis showed no difference in $CD3^+$ T cells and their subpopulations at 24 months between untreated and GLAT-treated pwCIS. Our results also showed that the percentage of $CD19^+CD20^+$ B cells were present at similar frequencies at baseline for both patient groups. However, while B cells increased at 24 months (GLAT=7.85 and Untreated= 5.47; [**% mean**]) in the GLAT-treated group, no significant difference was found (p=0.17). This non-statistically significant difference in the GLAT group appears to be secondary to an increased percentage of $CD20^+CD27^-$ naïve B cells ($p=0.06$). The percentage of $CD20^+CD27^+$ memory B cells was slightly reduced in the GLAT group at 24 months, whilst the untreated group had a little increase, but no significant difference was observed (p=0.18). No significant differences were observed in plasmablast percentages at 24 months.

Finally, we compared the proportions of B cell subsets ($CD27^-IgD^+$ naïve, $CD27^+IgD^+$ pre-switched memory, $CD27^+IgD^-$ switched memory, and $CD27^-IgD^-$ double negative) between untreated and GLAT-treated patients. Interestingly, we confirmed the tendency of the percentage of $CD20^+CD27^-IgD^+$ naïve B cells to increase within the group under GLAT after 24 months ($p=0.01$). Our results also showed that the percentage of $CD20^+CD27^+IgD^+$ pre-switched memory B cells in the GLAT group was lower at 24 months ($p=0.04$); in stark contrast to the GLAT group, pre-switched memory B cells tended to increase in the untreated group compared to baseline. In the GLAT group, the percentage of $CD20^+CD27^+IgD^-$ switched memory B cells decreased at 24 months, but it was not statistically significant (p=0.056). Lastly, our analysis did not show any substantial change in the percentage of $CD20^+CD27^-IgD^-$ double negative B cell subpopulation.

4. Discussion

Our observational explorative study aimed to characterise lymphocyte subsets after a first demyelinating event suggestive of MS. Our results showed early monocyte and B cell alterations in pwCIS using a broad immunophenotyping platform.

4.1 Differences between pwCIS and HDs

Results showed that the distribution of peripheral lymphocytes and monocytes differs between HDs and pwCIS. The percentage of lymphocytes in pwCIS is lower whilst the percentage of monocytes is higher compared to healthy individuals. Previous studies have highlighted the important role of monocytes in MS pathogenesis; they can contribute to the breakdown of the blood-brain barrier (Waschbisch et al., 2016). Furthermore, the T cell/monocyte ratio analysis has identified pwCIS at risk of rapid disease progression (Nemecek et al., 2016). In line with previous studies, our results encourage further characterisation of monocyte subsets (in connection with dynamic changes among B cell subsets) in pwCIS in future clinical research projects with large samples.

Within the T cell compartment, the distribution of CD4$^+$ cells did not show differences between HDs and pwCIS. Specifically, CD4$^+$ subpopulations expressing activation markers, such as CD38 and HLA-DR, did not differ from the aforementioned groups. Interestingly, the proportion of T regulatory cells (Tregs) was higher in pwCIS compared to HDs at baseline. However, a steady, higher proportion of peripheral Tregs did not seem to show any further benefit in preventing disease activity during the 24 months of follow-up; to confirm this tendency, it is necessary to conduct additional studies with a larger sample size.

Moreover, increasing evidence shows that several cell subsets contribute to the inflammatory cascade inside the CNS (Büdingen et al., 2012; Lisak et al., 2017; Stern et al., 2014). Our results showed that the percentage of CD19$^+$CD20$^+$ B cells was lower in pwCIS

compared to HDs. This is an interesting finding, considering that within the T cell compartment there was no or very little difference between groups. Our results are in line with Kreuzfelder *et al.* which showed that the percentage of peripheral CD19[+] cells in pwMS is lower than in HDs (Kreuzfelder et al., 2004). Whether this relatively low percentage of peripheral B cells is due to a higher monocyte proportion in pwCIS or to an active exchange between the periphery and CNS, including an increased influx of B cells into the inflamed CNS tissue, needs further investigation (Stern et al., 2014).

Intriguingly, a separate analysis of B cell subsets (with the CD19[+]CD20[-] plasmablast population excluded,) showed that the percentage of peripheral switched memory, pre-switched memory, and double negative B cell subpopulations are slightly higher in pwCIS, but the difference is not statistically significant; further studies with a larger sample size are needed to confirm this tendency.

4.2 Sub-analysis in pwCIS receiving GLAT

We also performed an ANCOVA analysis, as previously described, on two groups: untreated pwCIS and GLAT-treated pwCIS. Taken as a whole, lymphocytes and monocytes, we did not observe any significant change between those untreated compared to GLAT-treated individuals. We, nonetheless, observed a statistically non-significant increase in the percentage of B cells (among lymphocyte subsets) in those patients being treated with GLAT. Our results showed no significant changes within the plasmablast population (CD19[+]CD20[-]CD27[high]) subset.

Among B cell subsets, our analysis showed a higher percentage of naïve (p 0.01) and lower pre-switched memory (p 0.04) B cells after 24 months in the GLAT group, compared to the untreated group. Furthermore, whilst the percentage of switched memory B cells seemed to be reduced after 24 months in people receiving GLAT treatment, our analysis did not show a substantial change among groups at different time points (p=0.055); it would be worth exploring this outcome in further studies with a larger sample size, however.

Due to this study's explorative nature and aim, it is difficult to make assumptions about the therapeutic effect of GLAT in pwCIS, and therefore, our results are just observational; interindividual differences can also drive these changes. Interestingly, it has been observed that GLAT could affect various aspects of dysregulated B cells subsets in pwMS (Ireland et al., 2014; Kemmerer et al., 2020). Moreover, data from Häuser et al. showed that GLAT modulates B cells by downregulating the activation markers CD69, CD95, and CD25, decreasing TNF-α production, and increasing IL-10 secretion. GLAT also expands $CD4^+CD25^+FoxP3^+$ Treg cells (Häusler et al., 2020).

4.3 B cells and immune profiles in pwCIS and MS

Whilst B cells could overreact, generating a hostile and extreme autoimmune reaction, evidence has also shown that some subsets could regulate autoreactive T cell responses (Rieger & Bar-Or, 2008; Staun-Ram & Miller, 2017). For instance, it is believed that alemtuzumab depletes $CD19^+CD27^+$ B memory cells and allows a rapid repopulation of immature B cells (Baker, Herrod, Alvarez-Gonzalez, Giovannoni, et al., 2017). Furthermore, a new study by Ruck *et al.*, using an in-depth multidimensional immune phenotyping analysis, showed that the presence of hyperexpanded T cell clones might predict the development of secondary autoimmunity in some patients under alemtuzumab treatment. The effect of these T cell clones in MS pathophysiology is still unclear (Ruck et al., 2022). The depletion of peripheral B cells by anti-CD20 therapies shows that B cells play a key role in MS pathogenesis (Comi et al., 2021). However, the depletion of B cell subsets might not be enough to maintain an effective therapeutic outcome. Depletion of other reactive T cell subsets to obtain a more effective response might be needed. (Disanto et al., 2012; Graf et al., 2020) Moreover, some studies have found that the production of interleukin-10 (IL-10) by B cell subsets is a key factor for regulatory responses (Fillatreau et al., 2002, 2008; Rieger & Bar-Or, 2008). It has been proposed that IL-10 produced by naïve and memory B cells has a direct effect on activated Th1/Th17 and T regulatory cells to regulate immune responses in both health and pathological conditions (Fillatreau et al., 2008). Further

research is necessary to determine if lymphocyte immunophenotyping profiles in pwCIS can predict disease progression and/or guide personalised treatment decisions.

It is of note that we were unable to observe plasma cells (expression of CD138) in all measured samples. It seems that temporary circulating plasma cells are less likely to survive the freezing/thawing procedures applied to PBMCs. Moreover, in our study, we did not perform absolute counts due to the use of frozen samples. We propose that future lymphocyte immunophenotyping shall be performed in fresh blood and include absolute counting. This would not have been possible with the current methodology of this cohort. Moreover, it is important to mention that the decision to include only pwCIS using GLAT was influenced by factors beyond our control of this cohort; at the time of enrolment, GLAT was one of the most widely prescribed drugs to treat CIS/early MS.

Nevertheless, despite the limitations of this exploratory observational retrospective study and small sample size, we consider our results could encourage further research by using methodological assets of phenotypic and molecular studies to identify cellular biomarkers in these MS entities. In this study, we show that lymphocyte characterisation may be useful in characterising differences in peripheral lymphocyte subsets in pwCIS after a first demyelinating event.

5. Conclusion

In conclusion, our results showed early monocyte and B cell subsets alterations in pwCIS. Therefore, in future extensive clinical research, lymphocyte alterations found in our study could be considered to examine potential associations with ongoing MS activity after a first clinical manifestation. In addition, further inclusion of a wider immunophenotyping platform in larger cohorts could help to identify predictive immunological patterns.

Acknowledgements

We thank patients and healthy donors who participated in this study. We thank Rene M. Gieß, Bibiane Seeger-Schwinge, Gritt Stoeffels, Claudia Messelhauser and Katharina Stoesslein (NeuroCure Clinical Research Center, ECRC, Charité - Universitätsmedizin Berlin, Germany) for their technical assistance.

Funding & COI:

CAG received funding from the Mexican Government agency CONACYT (National Council of Science and Technology) for this project.

AW, **TD, and SS** declare to have no conflict of interest.

MSC has received fellowships from the Bayer Foundation and the Deutscher Akademischer Austauschdienst (DAAD) for her PhD studies.

CC received speaker and writing honoraria from Bayer and the British Society of Immunology, research support from Novartis and Alexion, unrelated to this current study. CC is a member of the Standing Committee on Science for the Canadian Institutes of Health Research.

JK received congress registration fees from Biogen and speaker honoraria from Sanofi Genzyme and Bayer Schering.

SA received congress registration fees from Biogen, and speaker honoraria from Alexion, Roche and Bayer Schering.

KR received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité (BIH Clinical Fellow Program) and Arthur Arnstein Foundation; received travel grants from Guthy-Jackson Charitable Foundation.

CID reports research grants from Novartis, Sanofi Genzyme and Deutsche Forschungsgemeinschaft (DFG; German Research Council) as well as conference honoraria from Sanofi Genzyme and Novartis.

JBS has received speaking honoraria and travel grants from Bayer Healthcare, and sanofi-aventis/Genzyme, in addition received compensation for serving on a scientific advisory board of Roche, unrelated to the presented work.

FP Reports research grants from German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel and Almirall. Payment honoraria from Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene. Support attending meetings from Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene. All unrelated to the present work.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to local regulations concerning the protection of patient data, but upon reasonable request, approval for distribution of data will be obtained from the institutional review board of Charité - Universitätsmedizin Berlin and anonymised data will be made available by the corresponding authors.

Competing interests

The authors declare that they have no competing interests.

Funding

The study was supported by the NeuroCure Clinical Research Center. **CAG** has received funding from the Mexican Government agency CONACYT (National Council of Science and Technology) for a post-doctoral fellowship to carry out this project and **MSC** received fellowships from the Deutscher Akademischer Austauschdienst (DAAD, Germany) and Bayer Foundation for her PhD studies.

Authors' contributions

CAG, AW, MSC, SS, CID, TD, FP: Conceived, designed the experiments and interpreted the data; CAG, AW: Performed the experiments; CAG, AW, MSC: Analysed the data; CAG, SS, CID, SA, JK, JB-S, CC, KR: Helped with patients' recruitment and clinical, MRI and/or laboratory data acquisition; CAG wrote the manuscript; CAG, CC, AW, MSC, SS, CID, TD, FP: Critically edited the manuscript.

Baker, D., Herrod, S. S., Alvarez-Gonzalez, C., Giovannoni, G., & Schmierer, K. (2017). Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. *JAMA Neurology*, *74*(8), 961–969. https://doi.org/10.1001/jamaneurol.2017.0676

Baker, D., Herrod, S. S., Alvarez-Gonzalez, C., Zalewski, L., Albor, C., & Schmierer, K. (2017). Both cladribine and alemtuzumab may effect MS via B-cell depletion. *Neurology(R) Neuroimmunology & Neuroinflammation*, *4*(4), e360. https://doi.org/10.1212/nxi.0000000000000360

Baker, D., Pryce, G., James, L. K., Schmierer, K., & Giovannoni, G. (2019). Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. *European Journal of Neurology*. https://doi.org/10.1111/ene.14105

Bittner, S., Ruck, T., Wiendl, H., Grauer, O. M., & Meuth, S. G. (2017). Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management. *Therapeutic Advances in Neurological Disorders*, *10*(1), 51–66. https://doi.org/10.1177/1756285616666741

Büdingen, H.-C. von, Kuo, T. C., Sirota, M., Belle, C. J. van, Apeltsin, L., Glanville, J., Cree, B. A., Gourraud, P.-A., Schwartzburg, A., Huerta, G., Telman, D., Sundar, P. D., Casey, T., Cox, D. R., & Hauser, S. L. (2012). B cell exchange across the blood-brain barrier in multiple sclerosis. *Journal of Clinical Investigation*, *122*(12), 4533–4543. https://doi.org/10.1172/jci63842

Cellerino, M., Ivaldi, F., Pardini, M., Rotta, G., Vila, G., Bäcker-Koduah, P., Berge, T., Laroni, A., Lapucci, C., Novi, G., Boffa, G., Sbragia, E., Palmeri, S., Asseyer, S., Høgestøl, E., Campi, C., Piana, M., Inglese, M., Paul, F., … Uccelli, A. (2020). Impact of treatment on cellular immunophenotype in MS: A cross-sectional study. *Neurology - Neuroimmunology Neuroinflammation*, *7*(3), e693. https://doi.org/10.1212/nxi.0000000000000693

Comi, G., Bar-Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Foundation, E. P. of the 27th A. M. of the E. C. (2021). Role of B Cells in Multiple Sclerosis and Related Disorders. *Annals of Neurology*, *89*(1), 13–23. https://doi.org/10.1002/ana.25927

Disanto, G., Morahan, J., Barnett, M., Giovannoni, G., & Ramagopalan, S. (2012). The evidence for a role of B cells in multiple sclerosis. *Neurology*, *78*(11), 823–832. https://doi.org/10.1212/wnl.0b013e318249f6f0

Fillatreau, S., Gray, D., & Anderton, S. M. (2008). Not always the bad guys: B cells as regulators of autoimmune pathology. *Nature Reviews Immunology*, *8*(5), nri2315. https://doi.org/10.1038/nri2315

Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002). B cells regulate autoimmunity by provision of IL-10. *Nature Immunology*, *3*(10), 944–950. https://doi.org/10.1038/ni833

Gelfand, J. M., Cree, B. A., & Hauser, S. L. (2017). Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. *Neurotherapeutics*, *14*(4), 835–841. https://doi.org/10.1007/s13311-017-0557-4

Gieß, R. M. M., Pfuhl, C., Behrens, J. R., Rasche, L., Freitag, E., Khalighy, N., Otto, C., Wuerfel, J., Brandt, A. U., Hofmann, J., Eberspächer, B., Bellmann-Strobl, J., Paul, F., & Ruprecht, K. (2017). Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. *PloS One*, *12*(4), e0175279. https://doi.org/10.1371/journal.pone.0175279

Graf, J., Mares, J., Barnett, M., Aktas, O., Albrecht, P., Zamvil, S. S., & Hartung, H.-P. (2020). Targeting B Cells to Modify MS, NMOSD, and MOGAD. *Neurology® Neuroimmunology & Neuroinflammation*, *8*(1), e918. https://doi.org/10.1212/nxi.0000000000000918

Greve, D. N., & Fischl, B. (2009). Accurate and robust brain image alignment using boundary-based registration. *NeuroImage*, *48*(1), 63–72. https://doi.org/10.1016/j.neuroimage.2009.06.060

Häusler, D., Hajiyeva, Z., Traub, J. W., Zamvil, S. S., Lalive, P. H., Brück, W., & Weber, M. S. (2020). Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS. *Neurology(R) Neuroimmunology & Neuroinflammation*, *3*, e698. https://doi.org/10.1212/nxi.0000000000000698

Ireland, S. J., Guzman, A. A., O'Brien, D. E., Hughes, S., Greenberg, B., Flores, A., Graves, D., Remington, G., Frohman, E. M., Davis, L. S., & Monson, N. L. (2014). The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis. *JAMA Neurology*, *71*(11), 1421–1428. https://doi.org/10.1001/jamaneurol.2014.1472

Jager, P. L. D., Rossin, E., Pyne, S., Tamayo, P., Ottoboni, L., Viglietta, V., Weiner, M., Soler, D., Izmailova, E., Faron-Yowe, L., O'Brien, C., Freeman, S., Granados, S., Parker, A., Roubenoff, R., Mesirov, J. P., Khoury, S. J., Hafler, D. A., & Weiner, H. L. (2008). Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. *Brain : A Journal of Neurology*, *131*(Pt 7), 1701–1711. https://doi.org/10.1093/brain/awn118

Kemmerer, C. L., Pernpeintner, V., Ruschil, C., Abdelhak, A., Scholl, M., Ziemann, U., Krumbholz, M., Hemmer, B., & Kowarik, M. C. (2020). Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab. *PLoS ONE*, *15*(7), e0235449. https://doi.org/10.1371/journal.pone.0235449

Kreuzfelder, E., Shen, G., Bittorf, M., Scheiermann, N., Thraenhart, O., Seidel, D., & Grosse-Wilde, H. (2004). Enumeration of T, B and Natural Killer Peripheral Blood Cells of Patients with Multiple Sclerosis and Controls. *European Neurology*, *32*(4), 190–194. https://doi.org/10.1159/000116820

Lassmann, H. (2019). The changing concepts in the neuropathology of acquired demyelinating central nervous system disorders. *Current Opinion in Neurology*, 1. https://doi.org/10.1097/wco.0000000000000685

Lin, T.-Y., Vitkova, V., Asseyer, S., Serra, I. M., Motamedi, S., Chien, C., Ditzhaus, M., Papadopoulou, A., Benkert, P., Kuhle, J., Bellmann-Strobl, J., Ruprecht, K., Paul, F., Brandt, A. U., & Zimmermann, H. G. (2021). Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. *Neurology - Neuroimmunology Neuroinflammation*, *8*(5), e1051. https://doi.org/10.1212/nxi.0000000000001051

Lisak, R. P., Nedelkoska, L., Benjamins, J. A., Schalk, D., Bealmear, B., Touil, H., Li, R., Muirhead, G., & Bar-Or, A. (2017). B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. *Journal of Neuroimmunology*, *309*, 88–99. https://doi.org/10.1016/j.jneuroim.2017.05.004

Nemecek, A., Zimmermann, H., Rübenthaler, J., Fleischer, V., Paterka, M., Luessi, F., Müller-Forell, W., Zipp, F., & Siffrin, V. (2016). Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression. *Multiple Sclerosis (Houndmills, Basingstoke, England)*, *22*(4), 483–493. https://doi.org/10.1177/1352458515593821

Pitt, D., Lo, C. H., Gauthier, S. A., Hickman, R. A., Longbrake, E., Airas, L. M., Mao-Draayer, Y., Riley, C., Jager, P. L. D., Wesley, S., Boster, A., Topalli, I., Bagnato, F., Mansoor, M., Stuve, O., Kister, I., Pelletier, D., Stathopoulos, P., Dutta, R., & Lincoln, M. R. (2022). Toward Precision Phenotyping of Multiple Sclerosis. *Neurology - Neuroimmunology Neuroinflammation*, *9*(6), e200025. https://doi.org/10.1212/nxi.0000000000200025

Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Montalban, X., O'Connor, P., Sandberg-Wollheim, M., Thompson, A. J., Waubant, E., Weinshenker, B., & Wolinsky, J. S. (2011). Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. *Annals of Neurology*, *69*(2), 292–302. https://doi.org/10.1002/ana.22366

Rasche, L., Scheel, M., Otte, K., Althoff, P., Vuuren, A. B. van, Gieß, R. M., Kuchling, J., Bellmann-Strobl, J., Ruprecht, K., Paul, F., Brandt, A. U., & Schmitz-Hübsch, T. (2018). MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study. *Frontiers in Neurology*, *9*, 718. https://doi.org/10.3389/fneur.2018.00718

Rieger, A., & Bar-Or, A. (2008). B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. *Nature Reviews Immunology*, *8*(6), 486–487. https://doi.org/10.1038/nri2315-c1

Roodselaar, J., Zhou, Y., Leppert, D., Hauser, A. E., Urich, E., & Anthony, D. C. (2021). Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis. *Neurology® Neuroimmunology & Neuroinflammation*, *8*(3), e975. https://doi.org/10.1212/nxi.0000000000000975

Ruck, T., Barman, S., Schulte-Mecklenbeck, A., Pfeuffer, S., Steffen, F., Nelke, C., Schroeter, C. B., Willison, A., Heming, M., Müntefering, T., Melzer, N., Krämer, J., Lindner, M., Riepenhausen, M., Gross, C. C., Klotz, L., Bittner, S., Muraro, P. A., Schneider-Hohendorf, T., … Wiendl, H. (2022). Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. *Brain*, *145*(5), 1711–1725. https://doi.org/10.1093/brain/awac064

Sèze, J. de, Maillart, E., Gueguen, A., Laplaud, D. A., Michel, L., Thouvenot, E., Zephir, H., Zimmer, L., Biotti, D., & Liblau, R. (2023). Anti-CD20 therapies in multiple sclerosis: From

pathology to the clinic. *Frontiers in Immunology*, *14*, 1004795.
https://doi.org/10.3389/fimmu.2023.1004795

Staun-Ram, E., & Miller, A. (2017). Effector and regulatory B cells in Multiple Sclerosis.
Clinical Immunology, *184*, 11–25. https://doi.org/10.1016/j.clim.2017.04.014

Staun-Ram, E., Najjar, E., Volkowich, A., & Miller, A. (2018). Dimethyl fumarate as a first- vs
second-line therapy in MS: Focus on B cells. *Neurology - Neuroimmunology
Neuroinflammation*, *5*(6), e508. https://doi.org/10.1212/nxi.0000000000000508

Stern, J. N. H., Yaari, G., Heiden, J. A. V., Church, G., Donahue, W. F., Hintzen, R. Q.,
Huttner, A. J., Laman, J. D., Nagra, R. M., Nylander, A., Pitt, D., Ramanan, S., Siddiqui,
B. A., Vigneault, F., Kleinstein, S. H., Hafler, D. A., & O'Connor, K. C. (2014). B cells
populating the multiple sclerosis brain mature in the draining cervical lymph nodes.
Science Translational Medicine, *6*(248), 248ra107.
https://doi.org/10.1126/scitranslmed.3008879

Waschbisch, A., Schröder, S., Schraudner, D., Sammet, L., Weksler, B., Melms, A.,
Pfeifenbring, S., Stadelmann, C., Schwab, S., & Linker, R. A. (2016). Pivotal Role for
CD16+ Monocytes in Immune Surveillance of the Central Nervous System. *Journal of
Immunology (Baltimore, Md.: 1950)*, 1558–1567.
https://doi.org/10.4049/jimmunol.1501960

Figure 1

Figure 1. Differences between pwCIS and HDs at Baseline. A) Mean percentage of lymphocytes and monocytes between isolated PBMCs. Mean percentage of CD3$^+$ T cells and CD19$^+$CD20$^+$ B cells in the lymphocyte population. B and C) Mean percentage of different T cell subpopulations in the lymphocyte population. D) Mean percentage of different B cell subpopulations in the lymphocyte population. E) Mean percentage of different B cell subpopulations in the CD20$^+$ subpopulation. Data are presented as mean percentage ± SD. Mann-Whitney test was utilised to compare the percentages between two unpaired groups. *$p\square$ 0.05, **$p\square$ 0.01, ***$p\square$ 0.001.

Table 1. Demographic and clinical characteristics of pwCIS and healthy donors

	HD	pwCIS Baseline*	pwCIS 12 months*	pwCIS 24 months*
Number, *n*	*15*	*20*	*20*	*20*
Untreated	-	10	10	10
GLAT	-	10	10	10
Age, years, median *(range)*	38.2(21-64)	32.5(24-47)	-	-
Untreated	-	33.5(25-44)	-	-
GLAT	-	31(24-47)	-	-
female/male, *n/n*	8/7	11/9	-	-
EDSS, median *(range)*	-			
Untreated	-	1.5(0-2.5)	1.5(0-2.5)	1.5(0-2)
GLAT	-	1.5(0-4)	1.5(0-4)	2(0-4.5)
MRI T2-hyperintense lesion count, median *(range)*				
Untreated	-	6(3-32)	0(0-12)	0(0-11)
GLAT	-	25(6-52)	2(0-11)	1(0-6; n=9)
Relapses, median *(range)*				
Untreated	-	-	0(0-1)	0(0-1)
GLAT	-	-	0(0-1)	0(0-1)

HD healthy donor, *pwCIS* patients with clinical isolated syndrome (CIS), *a.b.* after baseline, *n* number, *IQR* interquartile range, *"-"not* applicable, *EDSS* Expanded Disability Status Scale, *range* (minimum - maximum values), *GLAT* glatiramer acetate, *Untreated* treatment naïve, *At 3-6 (baseline), 12 and 24 months after baseline.

Table 2. Differences between pwCIS and HDs at Baseline

Lymphocyte subsets	pwCIS % (mean ±SD) n=19	HDs % (mean ±SD) n=15	p-value
CD3$^+$ (T cells)	76.6 (7.64)	75.8 (5.62)	0.56
CD4$^+$	50.9 (8.21)	50.3 (9.04)	0.86
CD4$^+$ CD38$^+$	6.68 (3.28)	5.89 (2.52)	0.63
CD4$^+$ HLA-DR$^+$	1.72 (0.693)	1.57 (0.996)	0.25
CD4$^+$CD38$^+$HLA-DR$^+$	0.33 (0.120)	0.23 (0.140)	0.015
CD4$^+$ CD25^{high}/CD127^{low} (Tregs)	3.75 (0.718)	2.70 (0.652)	< 0.001
CD19$^+$CD20$^+$ (B cells)	5.1 (2.37)	9.32 (2.98)	< 0.001
CD20$^+$CD27$^-$ (Naïve)	3.36 (2.04)	6.68 (3.27)	< 0.001
CD20$^+$CD27$^+$ Memory B cells	1.65 (0.792)	2.55 (1.00)	0.006
CD19$^+$CD20$^-$CD27^{high} Plasmablasts	0.047 (0.0358)	0.03 (0.0233)	0.17
B cell Subsets	**pwCIS % (mean ±SD) n=19**	**HDs % (mean ±SD) n=15**	**p-value**
CD20$^+$CD27$^-$ IgD$^+$ Naïve	59.45 (13.8)	64.26 (14.1)	0.354
CD20$^+$CD27$^+$IgD$^+$ pre-switched memory	14.43 (7.21)	13.20 (7.29)	0.471
CD20$^+$CD27$^+$IgD$^-$ switched memory	19.91 (7.92)	17.13 (8.42)	0.242
CD20$^+$CD27$^-$IgD$^-$ double negative	6.25 (3.19)	5.40 (3.63)	0.881

Mann-Whitney test was utilised to compare the percentages between two unpaired groups.

Table 3. ANCOVA model coefficients for predicting 24-months cell populations

Cell Population	Coefficients	Standardised Beta	SE	CI 95 lower	CI 95 upper	p value
Lymphocytes						
(Intercept)	32.6711343	10.05466579	15.07080339	0.548477255	64.79379134	0.046667598
Baseline	0.255622598	0.078668826	0.175033183	-0.117451801	0.628696997	0.164801666
12 months	0.388595167	0.11959164	0.149075744	0.07084774	0.706342593	0.019832798
24 months (Treatment)	-1.652892778	-0.508684036	1.623768442	-5.113873285	1.808087729	0.324846749
Monocytes						
(Intercept)	2.907089259	0.894667771	2.545658512	-2.518853418	8.333031937	0.271365117
Baseline	0.255622597	0.078668826	0.175033183	-0.117451802	0.628696996	0.164801667
12 months	0.388595167	0.11959164	0.149075744	0.07084774	0.706342595	0.019832798
24 months (Treatment)	1.652892779	0.508684036	1.623768443	-1.808087731	5.11387329	0.324846749

Lymphocyte subsets	Coefficients	Standardised Beta	SE	CI 95 lower	CI 95 upper	p value
CD3$^+$ (T cells)						
(Intercept)	4.634674386	1.158204247	9.781991234	-16.21514638	25.48449516	0.642467447
Baseline	0.464359707	0.116043402	0.303448824	-0.182426152	1.111145566	0.146762894
12 months	0.478285188	0.119523377	0.293995278	-0.148350913	1.104921289	0.124588703
24 months (Treatment)	-3.909265357	-0.976924668	1.911103975	-7.982687055	0.164156341	0.058753359
CD4$^+$						
(Intercept)	5.060631592	1.114920183	6.901123619	-9.648765209	19.77002839	0.474677677
Baseline	0.631819563	0.139197721	0.243229724	0.113387678	1.150251447	0.020194248
12 months	0.258963542	0.057052894	0.238629586	-0.249663381	0.767590465	0.294961916
24 months (Treatment)	-3.039536493	-0.669647755	2.178293428	-7.68245903	1.603386044	0.183218954
CD4$^+$CD38$^+$						
(Intercept)	0.513657604	0.250324591	1.186112388	-2.014481106	3.041796314	0.671133805
Baseline	0.496465429	0.2419462	0.310935202	-0.166277265	1.159208123	0.131184343
12 months	0.509589611	0.248342106	0.282444891	-0.092427424	1.111606646	0.091313509

24 months (Treatment)	-0.878825482	-0.428284577	0.956263761	-2.917053441	1.159402476	0.372627826
CD4$^+$HLA-DR$^+$						
(Intercept)	0.000235671	0.000697301	0.269009044	-0.573143534	0.573614876	0.999312541
Baseline	0.278319706	0.823488846	0.149756326	-0.040878347	0.597517759	0.082834827
12 months	0.810497989	2.398091259	0.207772949	0.367640431	1.253355546	0.001418671
24 months (Treatment)	-0.057038381	-0.168764446	0.181543118	-0.443988377	0.329911614	0.757706844
CD4$^+$CD38$^+$HLA-DR$^+$						
(Intercept)	0.179060843	1.84630234	0.071319036	0.027047917	0.331073769	0.023993344
Baseline	0.332575275	3.429194782	0.224757108	-0.14648316	0.81163371	0.159645476
12 months	0.081424468	0.839570411	0.173951403	-0.289344171	0.452193107	0.646451134
24 months (Treatment)	-0.065301179	-0.673322644	0.047300394	-0.166119583	0.035517225	0.18764002
CD4$^+$CD25^{high}CD127^{low} (Tregs)						
(Intercept)	0.488904646	0.585281377	1.054782919	-1.759311927	2.737121219	0.649651764
Baseline	0.481792304	0.576766994	0.455921538	-0.489981451	1.453566059	0.307351509
12 months	0.31547451	0.377663329	0.35177807	-0.434322698	1.065271719	0.383993293
24 months (Treatment)	-0.30831435	-0.369091701	0.411166027	-1.18469399	0.568065291	0.464942218
CD19$^+$CD20$^+$ (B cells)						
(Intercept)	1.675536544	0.87877138	1.163904521	-0.805267219	4.156340307	0.17052817
Baseline	0.369883754	0.193993535	0.345545485	-0.366629012	1.10639652	0.301346446
12 months	0.36033217	0.188984	0.28810398	-0.253746927	0.974411266	0.230201438
24 months (Treatment)	1.317850994	0.691175457	0.924241318	-0.652122743	3.287824731	0.174383893
CD19$^+$CD20$^+$CD27$^-$ (Naïve)						
(Intercept)	1.065685217	0.638672961	0.81751034	-0.676796826	2.80816726	0.212032155
Baseline	0.419818716	0.251600433	0.418534093	-0.472265587	1.311903018	0.331735125
12 months	0.271952936	0.162983387	0.341452844	-0.455836575	0.999742446	0.438190399
24 months (Treatment)	1.704572267	1.021562653	0.840398519	-0.086694774	3.495839308	0.06067375
CD19$^+$CD20$^+$CD27$^+$ (Memory B cells)						
(Intercept)	0.12007964	0.367291082	0.210455779	-0.328496234	0.568655513	0.576739614

B cell Subsets	Coefficients	Standardised Beta	SE	CI 95 lower	CI 95 upper	p value
Baseline	0.567547559	1.735974205	0.162742286	0.220670586	0.914424531	0.003307959
12 months	0.490877846	1.501462326	0.132084112	0.209347224	0.772408467	0.002068425
24 months (Treatment)	-0.211842516	-0.647968857	0.15269184	-0.537297469	0.113612438	0.185592873
CD19$^+$CD20$^-$CD27^{high} (Plasmablasts)						
(Intercept)	0.058397709	0.58781491	0.044709784	-0.03689894	0.153694358	0.211176713
Baseline	0.224393137	2.258678193	0.720096992	-1.310457269	1.759243542	0.759622198
12 months	-0.313132914	-3.151907827	0.562553981	-1.512188341	0.885922514	0.585991468
24 months (Treatment)	0.026361167	0.265344095	0.049530266	-0.079210096	0.131932431	0.602366253
B cell Subsets	**Coefficients**	**Standardised Beta**	**SE**	**CI 95 lower**	**CI 95 upper**	**p value**
CD20$^+$IgD$^+$CD27$^-$ Naive						
(Intercept)	-2.558607556	-0.436544058	6.228243434	-15.83379419	10.71657908	0.687022453
Baseline	0.648035144	0.110566347	0.252469356	0.10990945	1.186160838	0.021470855
12 months	0.367811916	0.062755269	0.248321345	-0.161472501	0.897096334	0.159254457
24 months (Treatment)	**7.813059882**	**1.33304729**	**2.985519018**	**1.449576729**	**14.17654304**	**0.019430341**
CD20$^+$IgD$^+$CD27$^+$ Memory-PreSwitched						
(Intercept)	3.527691836	1.014919234	2.504819758	-1.811205099	8.866588771	0.179413114
Baseline	0.780744544	0.224620713	0.321242019	0.096033388	1.4654557	0.02810216
12 months	0.147580009	0.042458865	0.273349717	-0.435051121	0.730211139	0.597194547
24 months (Treatment)	**-3.90278247**	**-1.122833053**	**1.768878247**	**-7.673057205**	**-0.132507736**	**0.043365763**
CD20$^+$IgD$^-$CD27$^+$ Memory-Switched						
(Intercept)	0.474251806	0.141451612	2.511876164	-4.879685503	5.828189115	0.852777355
Baseline	0.39291281	0.117191225	0.238027063	-0.114429866	0.900255486	0.119574905
12 months	0.609930722	0.181919568	0.261539315	0.052472867	1.167388577	0.03404247
24 months (Treatment)	-3.643413311	-1.086694194	1.755476108	-7.385122064	0.098295442	0.05555801
CD20$^+$IgD$^-$CD27$^-$ Double-Negative						
(Intercept)	0.859641429	0.821986286	0.633266189	-0.490133502	2.209416361	0.194704731

Baseline	0.028906528	0.027640326	0.155512031	-0.302559519	0.360372575	0.855029433
12 months	0.74285981	0.710320088	0.190965663	0.335826133	1.149893486	0.001450467
24 months (Treatment)	-0.006264152	-0.005989761	0.486302652	-1.042793719	1.030265415	0.989892355

Figure 1